National Institutes of Health, a Component of the US Dept. of Health & Human Services

Protein Potential, LLC

Other

Sanaria Inc.

Dennis J Kopecko

De-Qi Xu

John O Cisar

Stephen L Hoffman

B Kim Lee Sim

Yun Wu

Manuel Osorio

Deqi Xu

Milan S Blake

Chandrakant P Giri

Siba Bhattacharyya

Hajime Fukunaga

Madushini Nirosha Dharmasena

Monica R Foote

Disclosed is the attenuatedvaccine Ty21a utilized as a vector forand/or enterotoxogenicgenes stably integrated in the Ty21a chromosome. These genes include a heterologousO-antigen biosynthetic gene region that comprises the wzz gene and expressesform 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.

Live attenuated oral vaccine against shigellosis and typhoid fever

Live attenuated oral vaccine against ETEC and typhoid fever

A recombineeredTy21a, compositions and vaccines comprising such a Ty21a, and a method for recombineering comprising inserting a large antigenic region into a bacterial chromosome for the purpose of making multivalent vaccines to protect against one or more disease agents are described herein.

Multifunctional oral vaccine based on chromosome recombineering

Described herein is the generation of a plasmid construct for expression of aF1-V fusion protein. In the disclosed plasmid, the F1-V fusion protein coding sequence is operably linked to thehtrA promoter, and is fused in-frame to theHlyA secretion signal sequence. Also described isserovar Typhi strain Ty21a containing the F1-V fusion protein expression plasmid, such as for use as an oral vaccine against plague.

[object Object]

The invention relates toTy21a comprising core-linkedserotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encodingserotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.

Compositions and methods for protecting a susceptible host against an infection ofare disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.

[Problem] To provide M cells having excellent strength and anti-allergy activity and an artificial skin sheet formed from the M cells. [Solution] GP2 contained in the M cells is transferred to the intracellular tight junction and galectin 9 is expressed in the M cells. Moreover, a structure is formed in which both GP2 and galectin 9 are present at the M cell surface.

M cells and artificial skin sheet

Compositions and methods for protecting a susceptable host against an infection ofare disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.

The invention is related to intracellularly induced bacterial DNA promoters and vaccines against

Growing community of inventors

Silver Spring, MD, United States of America

Dennis J Kopecko